# A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate 

Source: https://onco.cc/trials/nct07213674/  
OnCo record `nct07213674` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Xaluritamig, Abiraterone acetate, Docetaxel in prostate cancer, run by Amgen, now recruiting.

## Summary

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer is a phase 3 interventional study registered as NCT07213674 by Amgen, with 750 participants planned, started 2025-11-28 and due to reach its primary completion in 2030-01-07. Interventions recorded: Xaluritamig, Abiraterone acetate, Docetaxel, Cabazitaxel. Conditions listed: Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07213674
- Phase: 3
- Setting: A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Sponsor: Amgen
- Enrolled: 750

## Sources

- ClinicalTrials.gov NCT07213674: https://clinicaltrials.gov/study/NCT07213674

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Cabazitaxel](https://onco.cc/drugs/cabazitaxel/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Xaluritamig](https://onco.cc/drugs/xaluritamig/)
- companies: [Amgen](https://onco.cc/companies/amgen/)

---
JSON: https://onco.cc/api/v1/entities/nct07213674.json